Refereed journal article or data article (A1)

PP2A methylesterase PME-1 suppresses anoikis and is associated with therapy relapse of PTEN-deficient prostate cancers




List of AuthorsAakula Anna, Isomursu Aleksi, Rupp Christian, Erickson Andrew, Gupta Nikhil, Kauko Otto, Shah Pragya, Padzik Artur, Pokharel Yuba Raj, Kaur Amanpreet, Li Song-Ping, Trotman Lloyd, Taimen Pekka, Rannikko Antti, Lammerding Jan, Paatero Ilkka, Mirtti Tuomas, Ivaska Johanna, Westermarck Jukka

PublisherWiley

Publication year2023

JournalMolecular Oncology

Journal name in sourceMolecular oncology

Journal acronymMol Oncol

Volume number17

Issue number6

ISSN1574-7891

eISSN1878-0261

DOIhttp://dx.doi.org/10.1002/1878-0261.13353

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/178512359


Abstract
While organ-confined prostate cancer (PCa) is mostly therapeutically manageable, metastatic progression of PCa remains an unmet clinical challenge. Resistance to anoikis, a form of cell death initiated by cell detachment from the surrounding extracellular matrix, is one of the cellular processes critical for PCa progression towards aggressive disease. Therefore, further understanding of anoikis regulation in PCa might provide therapeutic opportunities. Here, we discover that PCa tumors with concomitant inhibition of two tumor suppressor phosphatases, PP2A and PTEN, are particularly aggressive, having less than 50% 5-year secondary-therapy-free patient survival. Functionally, overexpression of PME-1, a methylesterase for the catalytic PP2A-C subunit, inhibits anoikis in PTEN-deficient PCa cells. In vivo, PME-1 inhibition increased apoptosis in in ovo PCa tumor xenografts, and attenuated PCa cell survival in zebrafish circulation. Molecularly, PME-1-deficient PC3 cells display increased trimethylation at lysines 9 and 27 of histone H3 (H3K9me3 and H3K27me3), a phenotype known to correlate with increased apoptosis sensitivity. In summary, our results demonstrate that PME-1 supports anoikis resistance in PTEN-deficient PCa cells. Clinically, these results identify PME-1 as a candidate biomarker for a subset of particularly aggressive PTEN-deficient PCa.

Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Last updated on 2023-05-09 at 07:59